Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Current Assets (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Current Assets data on record, last reported at $288.3 million in Q3 2025.

  • For Q3 2025, Current Assets fell 27.97% year-over-year to $288.3 million; the TTM value through Sep 2025 reached $288.3 million, down 27.97%, while the annual FY2024 figure was $386.1 million, 22.28% down from the prior year.
  • Current Assets reached $288.3 million in Q3 2025 per ZNTL's latest filing, down from $386.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $563.9 million in Q2 2023 and bottomed at $288.3 million in Q3 2025.
  • Average Current Assets over 4 years is $446.3 million, with a median of $442.9 million recorded in 2022.
  • Peak YoY movement for Current Assets: increased 22.81% in 2024, then decreased 27.97% in 2025.
  • A 4-year view of Current Assets shows it stood at $451.9 million in 2022, then rose by 9.91% to $496.7 million in 2023, then decreased by 22.28% to $386.1 million in 2024, then fell by 25.32% to $288.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $288.3 million in Q3 2025, $386.1 million in Q4 2024, and $400.3 million in Q3 2024.